Amsterdam

• Long-term safety and efficacy of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema attacks Ended
  2024-510777-18-00 5 2021-06-15 Hereditary angioedema
• A Study of BMS-986012 in Combination with Carboplatin, Etoposide, andNivolumab as First-line Therapy in Extensive-stage Small Cell Lung Canc … Ended
  2024-510700-36-00 4 2021-06-01 Extensive-stage Small Cell Lung Cancer
• Guanabenz in VWM Ended
  2023-503320-89-00 9 2021-05-31 Vanishing White Matter
• An open-label, long-term, safety and tolerability study of SAR445088 in participants with cold agglutinin disease previously treated with SA … Ended
  2023-510210-68-00 3 2021-05-26 Autoimmune haemolytic anaemia
• An Open-label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination with Atezolizumab in Patients with Locally Ad … Ended
  2023-506285-31-00 1 2021-04-21 Locally Advanced or Metastatic Solid Tumors
• A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study with a Long-Term Extension Treatment Period to Assess the … Ended
  2022-501188-42-00 4 2021-04-15 Early Alzheimer's Disease
• Dose Escalation of DF1001 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications Ended
  2023-503291-24-00 9 2021-03-17 Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected
• A Phase 3 Study to Evaluate the Efficacy and Safety of Darvadstrocel in the Treatment of Complex Perianal Fistula in Pediatric Subjects with … Ended
  2023-503973-39-00 5 2021-03-16 Complex Perianal Fistulas in Crohn's Disease
• VERDICT - Optimal Treatment Target in Active Ulcerative Colitis (UC) Ended
  2024-514183-21-00 6 2021-01-15 Ulcerative colitis
• A Phase I/IIb extension study assessing the long-term safety and efficacy of a gene therapy (AAV5-hFIX) previously administered to adult pat … Ended
  2024-512603-39-00 7 2021-01-08 Haemophilia B
• Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants wit … Ended
  2023-508443-40-00 5 2020-12-18 Lung Cancer, Non-Small Cell
• A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small C … Ended
  2024-516598-60-00 5 2020-12-18 Advanced Non-Squamous Non-Small Cell Lung Cancer
• An open-label Phase 1 study of NEO-PTC-01 in patients with advanced or metastatic melanoma Ended
  2023-508524-35-00 1 2020-12-01 Metastatic melanoma
• ISIS 721744-CS3: An Open-Label Extension Study of ISIS 721744 in Patients with Hereditary Angioedema Ended
  2024-517249-15-00 4 2020-10-22 Hereditary Angioedema
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease Ended
  2023-507303-55-00 4 2020-09-30 Alzheimer Disease
• A study to assess how ALZ-801 affects laboratory tests and symptoms of Alzheimer's disease in patients who have a specific genotype (APOE4). Ended
  2024-515858-25-00 4 2020-09-30 Subjects with a clinical diagnosis of Alzheimer's disease who are APOE
• Lutetium-177-PSMA in Oligo-metastatic Hormone Sensitive Prostate Cancer. Ended
  2023-509881-39-00 4 2020-07-27 prostate cancer
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV … Ended
  2023-507846-96-00 5 2020-06-19 Type 2 Diabetes Mellitus
• A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung) Ended
  2023-505035-12-00 5 2020-06-12 RET fusion−positive, metastatic Non-Small Cell Lung Cancer
• Double-blinded (treatment group unknown to physician and patient), randomised (treatment group allocated by chance) phase II trial on the ef … Ended
  2023-507897-42-00 4 2020-05-12 Prevention of oesophageal strictures in adult patients after endoscopi
• A Study to Evaluate Safety and Anti-Tumor Activity of RO7284755 Alone or in Combination with Atezolizumab in Participants with Advanced and/ … Ended
  2023-503749-76-00 1 2020-03-06 Solid Tumors
• A Phase 3 study of an Investigational Drug, Lumasiran (ALN-GO1) in patients with advanced primary hyperoxaluria Type 1 Ended
  2023-503382-29-00 5 2020-01-20 Primary Hyperoxaluria Type 1 (PH1)
• Safety, immunogenicity and preliminary clinical activity study of PDC*lung01 cancer vaccine in NSCLC Ended
  2024-517429-24-00 7 2020-01-09 Non-small-cell lung cancer
• Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinant … Ended
  2024-513074-22-00 4 2019-12-02 non-small cell lung cancer (NSCLC) of clinical stages IB, II and selec

Showing 1,033–1,056 of 1,112 trials